Direct-acting antivirals and host-targeting strategies to combat enterovirus infections

Tapparel, 2013, Picornavirus and enterovirus diversity with associated human diseases, Infect. Genet. Evol., 14, 282, 10.1016/j.meegid.2012.10.016 Bergelson, 2013, Picornavirus entry, Adv. Exp. Med. Biol., 790, 24, 10.1007/978-1-4614-7651-1_2 De Palma, 2008, Selective inhibitors of picornavirus replication, Med. Res. Rev., 28, 823, 10.1002/med.20125 Thibaut, 2012, Combating enterovirus replication: state-of-the-art on antiviral research, Biochem. Pharmacol., 83, 185, 10.1016/j.bcp.2011.08.016 van der Linden, 2015, Replication and inhibitors of enteroviruses and parechoviruses, Viruses, 7, 4529, 10.3390/v7082832 Abzug, 2016, A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis, J. Pediatric Infect. Dis. Soc., 5, 53, 10.1093/jpids/piv015 Pevear, 2005, Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses, Antimicrob. Agents Chemother., 49, 4492, 10.1128/AAC.49.11.4492-4499.2005 Benschop, 2015, Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient, J. Gen. Virol., 96, 571, 10.1099/vir.0.069773-0 Basta, 2014, Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance, Virology, 448, 82, 10.1016/j.virol.2013.10.004 Hao, 2012, Infection and propagation of human rhinovirus C in human airway epithelial cells, J. Virol., 86, 13524, 10.1128/JVI.02094-12 Liu, 2016, Atomic structure of a rhinovirus C, a virus species linked to severe childhood asthma, Proc. Natl. Acad. Sci. U. S. A., 113, 8997, 10.1073/pnas.1606595113 Baggen, 2016, Enterovirus D68 receptor requirements unveiled by haploid genetics, Proc. Natl. Acad. Sci. U. S. A., 113, 1399, 10.1073/pnas.1524498113 Liu, 2015, Sialic acid-dependent cell entry of human enterovirus D68, Nat. Commun., 6, 8865, 10.1038/ncomms9865 Stencel-Baerenwald, 2014, The sweet spot: defining virus-sialic acid interactions, Nat. Rev. Micro., 12, 739, 10.1038/nrmicro3346 Moss, 2012, A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection, J. Infect. Dis., 206, 1844, 10.1093/infdis/jis622 Nicholls, 2013, The use of sialidase therapy for respiratory viral infections, Antiviral Res., 98, 401, 10.1016/j.antiviral.2013.04.012 Rhoden, 2015, In vitro efficacy of antiviral compounds against enterovirus D68, Antimicrob. Agents Chemother., 59, 7779, 10.1128/AAC.00766-15 Matthews, 1999, Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes, Proc. Natl. Acad. Sci. U. S. A., 96, 11000, 10.1073/pnas.96.20.11000 Binford, 2005, Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor, Antimicrob. Agents Chemother., 49, 619, 10.1128/AAC.49.2.619-626.2005 Kaiser, 2000, In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses, Antiviral Res., 47, 215, 10.1016/S0166-3542(00)00106-6 Patick, 1999, In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease, Antimicrob. Agents Chemother., 43, 2444, 10.1128/AAC.43.10.2444 Hsyu, 2002, Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers, Antimicrob. Agents Chemother., 46, 392, 10.1128/AAC.46.2.392-397.2002 Zhang, 2001, Liquid chromatography–mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease, Drug Metab. Dispos., 29, 729 Hayden, 2003, Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers, Antimicrob. Agents Chemother., 47, 3907, 10.1128/AAC.47.12.3907-3916.2003 Patick, 2005, In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease, Antimicrob. Agents Chemother., 49, 2267, 10.1128/AAC.49.6.2267-2275.2005 Tan, 2013, 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses, J. Virol., 87, 4339, 10.1128/JVI.01123-12 Tan, 2016, Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease, Sci. Rep., 6, 33663, 10.1038/srep33663 Wu, 2016, Fragment-wise design of inhibitors to 3C proteinase from enterovirus 71, Biochim. Biophys. Acta, 1860, 1299, 10.1016/j.bbagen.2016.03.017 Ma, 2016, Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening, Eur. J. Med. Chem., 124, 981, 10.1016/j.ejmech.2016.10.019 Jordheim, 2013, Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases, Nat. Rev. Drug Discov., 12, 447, 10.1038/nrd4010 Pfeiffer, 2003, A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity, Proc. Natl. Acad. Sci. U. S. A., 100, 7289, 10.1073/pnas.1232294100 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 347, 975, 10.1056/NEJMoa020047 Deng, 2014, Inhibition of enterovirus 71 by adenosine analog NITD008, J. Virol., 88, 11915, 10.1128/JVI.01207-14 Kang, 2015, Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses, Antiviral Res., 124, 1, 10.1016/j.antiviral.2015.10.011 Zhang, 2016, Cell-based high-throughput screening assay identifies 2′,2′-difluoro-2′-deoxycytidine Gemcitabine as potential anti-poliovirus agent, ACS Infect, Dis., 2017, 45 van der Linden, 2015, The RNA template channel of the RNA-dependent RNA polymerase as a target for development of antiviral therapy of multiple genera within a virus family, PLoS Pathog., 11, e1004733, 10.1371/journal.ppat.1004733 Liu, 2016, SUMO modification stabilizes enterovirus 71 polymerase 3D to facilitate viral replication, J. Virol., 90, 10472, 10.1128/JVI.01756-16 Ulferts, 2016, Screening of a library of FDA-approved drugs identifies several enterovirus replication inhibitors that target viral protein 2C, Antimicrob. Agents Chemother., 60, 2627, 10.1128/AAC.02182-15 Ulferts, 2013, Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C, Antimicrob. Agents Chemother., 57, 1952, 10.1128/AAC.02084-12 Zuo, 2012, Fluoxetine is a potent inhibitor of coxsackievirus replication, Antimicrob. Agents Chemother., 56, 4838, 10.1128/AAC.00983-12 Xia, 2015, Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP-independent RNA chaperone, PLoS Pathog., 11, e1005067, 10.1371/journal.ppat.1005067 Gofshteyn, 2016, Treatment of chronic enterovirus encephalitis with fluoxetine in a patient with X-linked Agammaglobulinemia, Pediatr. Neurol., 64:94 Jiang, 2014, Picornavirus morphogenesis, Microbiol. Mol. Biol. Rev., 78, 418, 10.1128/MMBR.00012-14 Geller, 2007, Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance, Genes. Dev., 21, 195, 10.1101/gad.1505307 Ma, 2014, An interaction between glutathione and the capsid is required for the morphogenesis of C-cluster enteroviruses, PLoS Pathog., 10, e1004052, 10.1371/journal.ppat.1004052 Thibaut, 2014, Binding of glutathione to enterovirus capsids is essential for virion morphogenesis, PLoS Pathog., 10, e1004039, 10.1371/journal.ppat.1004039 Asare, 2016, A single amino acid substitution in poliovirus nonstructural protein 2CATPase causes conditional defects in encapsidation and uncoating, J. Virol., 90, 6174, 10.1128/JVI.02877-15 Liu, 2010, Direct interaction between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for enterovirus morphogenesis, PLoS Pathog., 6, e1001066, 10.1371/journal.ppat.1001066 Wang, 2012, Alanine scanning of poliovirus 2CATPase reveals new genetic evidence that capsid protein/2CATPase interactions are essential for morphogenesis, J. Virol., 86, 9964, 10.1128/JVI.00914-12 Tsou, 2013, Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy, PLoS One, 8, e77133, 10.1371/journal.pone.0077133 van der Schaar, 2016, Fat(al) attraction: picornaviruses usurp lipid transfer at membrane contact sites to create replication organelles, Trends Microbiol., 24, 535, 10.1016/j.tim.2016.02.017 Hsu, 2010, Viral reorganization of the secretory pathway generates distinct organelles for RNA replication, Cell, 141, 799, 10.1016/j.cell.2010.03.050 van der Schaar, 2013, A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIbeta, Antimicrob. Agents Chemother., 57, 4971, 10.1128/AAC.01175-13 Arita, 2011, Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity, J. Virol., 85, 2364, 10.1128/JVI.02249-10 Roulin, 2014, Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface, Cell Host Microbe, 16, 677, 10.1016/j.chom.2014.10.003 Lamarche, 2012, Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors, Antimicrob. Agents Chemother., 56, 5149, 10.1128/AAC.00946-12 Arita, 2016, Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III beta inhibitor, ACS Infect. Dis., 2, 140, 10.1021/acsinfecdis.5b00122 van der Schaar, 2012, Coxsackievirus mutants that can bypass host factor PI4KIIIbeta and the need for high levels of PI4P lipids for replication, Cell Res., 22, 1576, 10.1038/cr.2012.129 Strating, 2015, Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein, Cell Rep., 10, 600, 10.1016/j.celrep.2014.12.054 Gao, 2015, Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A, Antimicrob. Agents Chemother., 59, 2654, 10.1128/AAC.05108-14 Mesmin, 2013, A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP, Cell, 155, 830, 10.1016/j.cell.2013.09.056 Albulescu, 2015, Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP, Antiviral Res., 117, 110, 10.1016/j.antiviral.2015.02.013 Arita, 2013, Oxysterol-binding protein family I is the target of minor enviroxime-like compounds, J. Virol., 87, 4252, 10.1128/JVI.03546-12 Albulescu, 2017, Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307, Antiviral Res., 140, 37, 10.1016/j.antiviral.2017.01.008 Shim, 2016, Therapeutic and prophylactic activity of itraconazole against human rhinovirus infection in a murine model, Sci. Rep., 6, 23110, 10.1038/srep23110 Qing, 2014, Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator, PLoS Pathog., 10, e1004422, 10.1371/journal.ppat.1004422 Frausto, 2013, Cyclophilins as modulators of viral replication, Viruses, 5, 1684, 10.3390/v5071684 Seizer, 2012, Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis, J. Mol. Cell Cardiol., 53, 6, 10.1016/j.yjmcc.2012.03.004 Desmet, 2014, Structural basis of IL-23 antagonism by an Alphabody protein scaffold, Nat. Commun., 5, 5237, 10.1038/ncomms6237 Crotty, 2001, The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen, Nat. Med., 7, 255